ɬŔď·¬

Journal News

Seeking to cure a coronavirus fatal to cats

Sneha Das
July 18, 2023

All of us have witnessed the impact of the caused by the SARS-CoV-2 that claimed more than 6 million lives worldwide. The coronavirus family is made up of RNA viruses that infect many mammals and birds. In humans, outcomes can range from the common cold to fatal . 

Like humans, cats can be infected by coronaviruses. Most cats are exposed as kittens to the feline alphacoronavirus, or FCoV. One found that 40% of domestic cats in the United Kingdom had antibodies for FCoV, suggesting prior infection. Most FCoV infections are asymptomatic or cause mild disease in the gastrointestinal tract. However, in 5% of cases, the virus spreads and results in a fatal disease called , or FIP. Experts believe that the gastrointestinal coronavirus strain can mutate into the more that causes FIP.

, an assistant professor at the Western University of Health Sciences in California studies infectious diseases caused by RNA viruses.

“FIP is a devastating disease that affects cats worldwide,” Mir said, “and currently, there are no effective treatments available for this condition.”

A coronavirus enters a host cell and multiplies there before exiting to infect new cells. Before the virus exits, it makes multiple copies of its RNA and packages it into its nucleocapsid, an outer shell that protects the viral RNA outside the host.

Mir’s group found that a novel compound called K31 targets the nucleocapsid protein of FCoV and stops it from multiplying. In cell culture models, the virus was undetectable 24 hours after treatment with a single dose of K31. The researchers reported this discovery in a published in the Journal of Biological Chemistry.

How does K31 inhibit the virus at the molecular level? When nucleocapsids are packaged with viral RNA, they form ribonucleocapsids, which coronaviruses rely on to make more copies of the viral RNA. K31 disrupts the structural integrity of these ribonucleocapsids, and this has a catastrophic effect on the virus within the host.

“Cell culture studies are useful for the initial screening of potential compounds, and this study provides a promising starting point,” Mir said. “The identification of K31 is an exciting development, but more research is needed to evaluate its effectiveness and safety in living animals.”

Mir’s group previously found that K31 inhibits the and a new world hantavirus that causes in humans. Initial cell culture studies suggest that K31 is well tolerated by host cells and might be developed into a broad-spectrum antiviral as well as an anti-coronavirus drug.

Previous has focused on targets such as RNA-dependent RNA polymerase, spike protein, and envelope protein, Mir said, but this study shows the nucleocapsid is also a druggable target.

FIP kills worldwide. According to Mir, targeted therapies with compounds like K31 could soon be an effective treatment with minimal side effects.

“It is exciting to see that our research project has identified a novel molecule that has potential for further development as an antiviral therapy,” Mir said. “It offers hope to cat owners.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Sneha Das

Sneha Das is a research development manager at the University of Illinois at Urbana–Champaign and an ASBMB Today volunteer contributing writer.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Teaching AI to listen
Essay

Teaching AI to listen

Sept. 18, 2025

A computational medicine graduate student reflects on building natural language processing tools that extract meaning from messy clinical notes — transforming how we identify genetic risk while redefining what it means to listen in science.

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Journal News

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder

Sept. 16, 2025

Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.

How sugars shape Marfan syndrome
Journal News

How sugars shape Marfan syndrome

Sept. 10, 2025

Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.